| 265 | 3 | 55 |
| 下载次数 | 被引频次 | 阅读次数 |
卵巢恶性肿瘤患者是静脉血栓防治的高危人群。针对1例复发转移卵巢癌患者应用贝伐珠单抗联合化疗并发上肢静脉血栓形成的病例，临床药师在药物治疗实践中结合国内外指南，从抗凝药物的选择、剂量、疗程及相关不良反应防治等方面提供个体化抗凝药学监护，提高了中晚期卵巢癌患者抗凝治疗用药的疗效及安全性。同时协助临床医师制订个体化的抗肿瘤治疗方案，开展抗肿瘤用药不良反应监测和管理，最大限度地延长患者生存期和改善患者的生存质量。
Abstract：[1]KEY N S,KHORANA A A,KUDERER N M,et al.Venous thromboembolism prophylaxis and treatment in patients with cancer:ASCO clinical practice guideline update[J].J Clin Oncol,2020,38(5):496.
[2]STREIFF M B,HOLMSTROM B,ANGELINI D,et al.Cancerassociated venous thromboembolic disease,version 2.2021,NCCNclinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2021,19(10):1181.
[3]李晓,姜洁,尹如铁,等.妇科肿瘤抗血管内皮生长因子单克隆抗体临床应用指南[J].中国医学前沿杂志(电子版),2020,12(1):27.
[4]张亚同,车宁,朱翊,等.利伐沙班与依诺肝素用于恶性肿瘤合并静脉血栓栓塞症疗效与安全性比较的Meta分析[J].中国药房,2021,32(4):485.
[5]de ATHAYDE SOARES R,MATIELO M F,BROCHADO NETO FC,et al.Ultrasound aspects and recanalization rates in patients with lower-limb deep venous thrombosis treated with rivaroxaban[J].Ann Vasc Surg,2020,67:293.
[6]LAUBE E S,MANTHA S,SAMEDY P,et al.Treatment of central venous catheter-associated deep venous thrombosis in cancer patients with rivaroxaban[J].Am J Hematol,2017,92(1):E9.
[7]de ATHAYDE SOARES R,MATIELO M F,BROCHADO NETO FC,et al.Comparison of the recanalization rate and postthrombotic syndrome in patients with deep venous thrombosis treated with rivaroxaban or warfarin[J].Surgery,2019,166(6):1076.
[8]LYMAN G H,CARRIER M,AY C,et al.American Society of Hematology 2021 guidel ines for management of venous thromboembolism:prevention and treatment in patients with cancer[J].Blood Adv,2021,5(4):927.
[9]范琼,王玉东.妇科疾病常见引发静脉血栓栓塞症的高危因素[J].中国计划生育和妇产科,2021,13(3):22.
[10]黄雨涵,李希,张艳.术后深静脉血栓与卵巢癌预后的相关性分析[J].现代妇产科进展,2019,28(11):829.
[11]EINSTEIN M H,PRITTS E A,HARTENBACH E M.Venous thromboembolism prevention in gynecologic cancer surgery:a systematic review[J].Gynecol Oncol,2007,105(3):813.
[12]WANG T F,ZWICKER J I,AY C,et al.The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients:guidance from the SSC of the ISTH[J].J Thromb Haemost,2019,17(10):1772.
[13]马军,秦叔逵,吴一龙,等.肿瘤相关静脉血栓栓塞症预防与治疗指南(2019版)[J].中国肿瘤临床,2019,46(13):653.
[14]祖逸峥,马少寒,李茹月,等.贝伐单抗联合白蛋白结合型紫杉醇治疗复发性卵巢癌临床疗效的Meta分析[J].宁夏医科大学学报,2021,43(10):1029.
[15]NALLURI S R,CHU D,KERESZTES R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis[J].JAMA,2008,300(19):2277.
[16]张伯玮,任静,马睿,等.D-二聚体在静脉血栓栓塞症诊疗中的应用临床实践[J].诊断学理论与实践,2020,19(5):469.
[17]李宜瑶,施举红.肿瘤患者静脉血栓栓塞抗凝出血与复发风险研究进展[J].中国肿瘤临床,2020,47(24):1287.
[18]马旭,韩森,方健.肿瘤相关静脉血栓栓塞症中新型口服抗凝药应用进展[J].中华肿瘤防治杂志,2021,28(3):237.
[19]GIUSTOZZI M,AGNELLI G,DEL TORO-CERVERA J,et al.Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer:a systematic review and meta-analysis[J].Thromb Haemost,2020,120(7):1128.
[20]KANDEMIR E A,BAYRAKTAR-EKINCIOGLU A,KILICKAPS.Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy[J].Support Care Cancer,2021,29(3):1699.
基本信息:
DOI：10.19577/j.1007-4406.2022.04.015
中图分类号:R737.31
引用信息:
[1]徐蕊,杜琼,阮聪,等.临床药师参与1例复发转移卵巢癌患者静脉血栓形成的药学实践[J].中国临床药学杂志,2022,31(04):308-312.DOI:10.19577/j.1007-4406.2022.04.015.
基金信息:
上海市闵行区卫生健康委员会科研课题（编号2020MW47）; 闵行区卫生健康委员会科研课题（编号mwyjyx03）; 上海市科学技术委员会科研项目（编号19DZ1910705）
2022-04-25
2022-04-25